Double Helix Biotechnology Dev. has been acquired by Interpublic Group of Companies

Double Helix Bio-Technology Development Ltd. (Double Helix), a leading, global provider of market research and market access services to the pharmaceutical and medical device industries, has been sold to McCann Health, owned by The Interpublic Group of Companies Inc. Financial details of this transaction have not been disclosed.

Founded by Dr Wayne Phillips and based in London, Double Helix not only specializes in the established markets of the US and Europe, but also focuses on emerging markets, providing clients with a truly global perspective. In the past year, Double Helix has performed projects across more than 40 countries for over 30 major pharmaceutical multinational clients. Dr Phillips will continue as CEO of Double Helix, reporting to John Cahill, CEO of McCann Health.

McCann Health is a part of McCann Worldgroup, the largest marketing communications agency network in the world, and is a leading healthcare agency network owned by The Interpublic Group of Companies Inc.

Oaklins Cavendish, based in the UK, acted as financial advisor to the seller.